SK
Scott Kelley
Chief Medical Officer

Scott Kelley insider trades: Flexion Therapeutics (FLXN) stock buys and sales

Chief Medical Officer, Flexion Therapeutics Last trade Jan 5, 2021 24 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
6
Open-market trades
since 2005
2
Companies
last trade 2021

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Scott reports to the SEC

Open-market buys and sales

6 trades reported on SEC Form 4, newest first

DateStockTypeValue
Jan 5, 2021FLXN↓ Sell$76K
Jan 3, 2019FLXN↓ Sell10b5-1$8K
Dec 16, 2008ASPM↑ Buy$13K
Nov 2, 2005ASPM↓ Sell$889K
Oct 25, 2005ASPM↓ Sell$43K
Jul 29, 2005ASPM↓ Sell$310K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

About Scott Kelley's insider trades

Scott Kelley is Chief Medical Officer at Flexion Therapeutics (FLXN). Since Jul 29, 2005, Scott has reported 1 open-market purchase worth $13K and 5 sales worth $1.3M on SEC Form 4. There have been no open-market trades in the last 12 months.

1 sale (1% of the value sold) was made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so it says little about how the insider sees the stock today.

Their filings also include grants and awards (11 filings), other transactions (3 filings), option exercises (3 filings), shares withheld for taxes (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every FLXN insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.